doi: 10.1177/1756287210375270.
Hormone therapy in the management of prostate cancer: evidence-based approaches
Affiliations
- PMID: 21789093
- PMCID: PMC3126080
- DOI: 10.1177/1756287210375270
Item in Clipboard
Hormone therapy in the management of prostate cancer: evidence-based approaches
Ther Adv Urol.
2010 Aug.
Abstract
Hormonal therapy has been the standard for advanced prostate cancer for over 60 years. Recently, the utility of androgen ablation through various means has been demonstrated for earlier stages of disease. In particular, the strongest evidence to date involves the use of hormonal therapy in combination with radiation therapy. In this article we review the basic concepts in hormonal ablation for prostate cancer and review the evidence-based studies that support the use of hormonal therapy in early stage prostate cancer.
Keywords: androgen deprivation therapy; combined androgen blockade; hormonal therapy; prostate cancer.
Similar articles
-
Medical therapy of prostate cancer. A review.Minerva Urol Nefrol. 2005 Jun;57(2):71-84. Minerva Urol Nefrol. 2005. PMID: 15951731 Review.
-
Targeting Metastatic Hormone Sensitive Prostate Cancer: Chemohormonal Therapy and New Combinatorial Approaches.J Urol. 2019 May;201(5):876-885. doi: 10.1097/JU.0000000000000117. J Urol. 2019. PMID: 30747897 Review.
-
The selection of hormonal therapy in prostate cancer: who, when, and for how long?J Natl Compr Canc Netw. 2004 May;2(3):261-8. doi: 10.6004/jnccn.2004.0023. J Natl Compr Canc Netw. 2004. PMID: 19795609 Review.
-
Endocrine treatment of prostate cancer.J Steroid Biochem Mol Biol. 2004 Nov;92(4):287-95. doi: 10.1016/j.jsbmb.2004.10.005. Epub 2004 Dec 31. J Steroid Biochem Mol Biol. 2004. PMID: 15663992 Review.
-
Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for metastatic hormone-sensitive prostate cancer.Cochrane Database Syst Rev. 2020 Dec 12;12(12):CD013245. doi: 10.1002/14651858.CD013245.pub2. Cochrane Database Syst Rev. 2020. PMID: 33314020 Free PMC article.
Cited by
-
From sequence to molecular pathology, and a mechanism driving the neuroendocrine phenotype in prostate cancer.J Pathol. 2012 Jul;227(3):286-97. doi: 10.1002/path.4047. J Pathol. 2012. PMID: 22553170 Free PMC article.
-
Adjuvant hormone therapy after radical prostatectomy in high-risk localized and locally advanced prostate cancer: First multicenter, observational study in China.Chin J Cancer Res. 2019 Jun;31(3):511-520. doi: 10.21147/j.issn.1000-9604.2019.03.13. Chin J Cancer Res. 2019. PMID: 31354220 Free PMC article.
-
LHRH Agonists for the Treatment of Prostate Cancer: 2012.Rev Urol. 2012;14(1-2):1-12. Rev Urol. 2012. PMID: 23172994 Free PMC article.
-
What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 4: Experimental Treatments in Pre-Clinical Studies (Cell Lines and Mouse Models).Int J Mol Sci. 2021 Nov 14;22(22):12297. doi: 10.3390/ijms222212297. Int J Mol Sci. 2021. PMID: 34830179 Free PMC article.
-
miR-30e* is overexpressed in prostate cancer and promotes NF-κB-mediated proliferation and tumor growth.Oncotarget. 2017 Jun 28;8(40):67626-67638. doi: 10.18632/oncotarget.18795. eCollection 2017 Sep 15. Oncotarget. 2017. PMID: 28978058 Free PMC article.
References
-
- Abrahamsson P.A. (2010) Potential benefits of intermittent androgen suppression therapy in the treatment of prostate cancer: a systematic review of the literature. Eur Urol 57: 49–59 - PubMed
-
- Akaza H., Hinotsu S., Usami M., Arai Y., Kanetake H., Naito S., et al. (2009) Combined androgen blockade with bicalutamide for advanced prostate cancer: long-term follow-up of a phase 3, double-blind, randomized study for survival. Cancer 115: 3437–3445 - PubMed
-
- Arai Y., Akaza H., Deguchi T., Fujisawa M., Hayashi M., Hirao Y., et al. (2008) Evaluation of quality of life in patients with previously untreated advanced prostate cancer receiving maximum androgen blockade therapy or LHRHa monotherapy: a multicenter, randomized, doubleblind, comparative study. J Cancer Res Clin Oncol 134: 1385–1396 - PubMed
-
- Aus G., Abrahamsson P.A., Ahlgren G., Hugosson J., Lundberg S., Schain M., et al. (2002) Three-month neoadjuvant hormonal therapy before radical prostatectomy: a 7-year follow-up of a randomized controlled trial. BJU Int 90: 561–566 - PubMed
-
- Bolla M., Collette L., Blank L., Warde P., Dubois J.B., Mirimanoff R.O., et al. (2002) Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomized trial. Lancet 360: 103–106 - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources
